Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial (vol 6, pg 747, 2018)

被引：0
|
作者：
Ferguson, G. T.
Rabe, K. F.
Martinez, F. J.
机构：
来源：
LANCET RESPIRATORY MEDICINE | 2019年 / 7卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：E9 / E9
页数：1
相关论文
共 15 条
  • [1] Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
    Ferguson, Gary T.
    Rabe, Klaus F.
    Martinez, Fernando J.
    Fabbri, Leonardo M.
    Wang, Chen
    Ichinose, Masakazu
    Bourne, Eric
    Ballal, Shaila
    Darken, Patrick
    DeAngelis, Kiernan
    Aurivillius, Magnus
    Dorinsky, Paul
    Reisner, Colin
    LANCET RESPIRATORY MEDICINE, 2018, 6 (10): : 747 - 758
  • [2] Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial (vol 18, pg 327, 2018)
    Ferguson, G. T.
    Rabe, K. F.
    Martinez, F. J.
    LANCET RESPIRATORY MEDICINE, 2018, 6 (11): : E55 - E55
  • [3] Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial (vol 391, pg 1076, 2018)
    Papi, A.
    Vestbo, J.
    Fabbri, L.
    LANCET, 2018, 391 (10125): : 1022 - 1022
  • [4] Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial
    Papi, Alberto
    Vestbo, Jorgen
    Fabbri, Leonardo
    Corradi, Massimo
    Prunier, Helene
    Cohuet, Geraldine
    Guasconi, Alessandro
    Montagna, Isabella
    Vezzoli, Stefano
    Petruzzelli, Stefano
    Scuri, Mario
    Roche, Nicolas
    Singh, Dave
    LANCET, 2018, 391 (10125): : 1076 - 1084
  • [5] Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease A Randomized, Double-Blind, Multicenter, Parallel-Group Study
    Martinez, Fernando J.
    Rabe, Klaus F.
    Ferguson, Gary T.
    Wedzicha, Jadwiga A.
    Singh, Dave
    Wang, Chen
    Rossman, Kimberly
    St Rose, Earl
    Trivedi, Roopa
    Ballal, Shaila
    Darken, Patrick
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (05) : 553 - 564
  • [6] Cardiovascular Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Chronic Obstructive Pulmonary Disease (COPD): A 24-Hour Hotter Monitoring Sub-Study of the ETHOS Trial
    Ferguson, G. T.
    Rabe, K. F.
    Martinez, F. J.
    Trivedi, R.
    St Rose, E.
    Ballal, S.
    Darken, P.
    Aurivillius, M.
    Dorinsky, P.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [7] Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial
    Vestbo, Jorgen
    Papi, Alberto
    Corradi, Massimo
    Blazhko, Viktor
    Montagna, Isabella
    Francisco, Catherine
    Cohuet, Geraldine
    Vezzoli, Stefano
    Scuri, Mario
    Singh, Dave
    LANCET, 2017, 389 (10082): : 1919 - 1929
  • [8] Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial
    Singh, Dave
    Papi, Alberto
    Corradi, Massimo
    Pavlisova, Ilona
    Montagna, Isabella
    Francisco, Catherine
    Cohuet, Geraldine
    Vezzoli, Stefano
    Scuri, Mario
    Vestbo, Jorgen
    LANCET, 2016, 388 (10048): : 963 - 973
  • [9] Exenatide once a week versus placebo as apotential disease- modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
    Vijiaratnam, Nirosen
    Girges, Christine
    Auld, Grace
    Mccomish, Rachel
    King, Alexa
    Skene, Simon S.
    Hibbert, Steve
    Wong, Alan
    Melander, Sabina
    Gibson, Rachel
    Matthews, Helen
    Dickson, John
    Carroll, Camille
    Patrick, Abigail
    Inches, Jemma
    Silverdale, Monty
    Blackledge, Bethan
    Whiston, Jessica
    Hu, Michele
    Welch, Jessica
    Duncan, Gordon
    Power, Katie
    Gallen, Sarah
    Kerr, Jacqueline
    Chaudhuri, K. Ray
    Batzu, Lucia
    Rota, Silvia
    Jabbari, Edwin
    Morris, Huw
    Limousin, Patricia
    Greig, Nigel
    Li, Yazhou
    Libri, Vincenzo
    Gandhi, Sonia
    Athauda, Dilan
    Chowdhury, Kashfia
    Foltynie, Tom
    LANCET, 2025, 405 (10479): : 627 - 636
  • [10] Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial (vol 395, pg 1496, 2020)
    McInnes, I. B.
    Behrens, F.
    Mease, P. J.
    Kavanaugh, Arthur
    Ritchlin, Christopher
    Nash, Peter
    Masmitja, Jordi Gratacos
    Goupille, Philippe
    Korotaeva, Tatiana
    Gottlieb, Alice B.
    Martin, Ruvie
    Ding, Kevin
    Pellet, Pascale
    Mpofu, Shephard
    Pricop, Luminita
    LANCET, 2020, 395 (10238): : 1694 - 1694
12